Search

Displaying results 911 - 920 of 4344 in total
  1. Drug

    Fosfomycin

    go.drugbank.com/drugs/DB00828
    ApprovedInvestigational

    Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by _Streptomyces fradiae_.

    Products: FOMAXIN ® 40MG/ML
  2. Drug

    Zolmitriptan

    go.drugbank.com/drugs/DB00315
    ApprovedInvestigational

    [A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. … [A193797] Zolmitriptan was first approved by the FDA for sale by Zeneca Pharmaceuticals under the trade name Zomig® on November 25, 1997.

  3. Drug

    Triclabendazole

    go.drugbank.com/drugs/DB12245
    ApprovedInvestigational

    Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. … Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.

  4. Drug

    Quinagolide

    go.drugbank.com/drugs/DB09097
    ApprovedWithdrawn

    Quinagolide is currently available in several countries including Canada, but not approved for treatment in the United States. … Quinagolide exists as a racemate and its relevant clinical activity is mediated predominantly by the (-) enantiomer.

  5. Drug

    Copper gluconate

    go.drugbank.com/drugs/DB11246
    ApprovedInvestigational

    It is prepared by the reaction of gluconic acid solutions with cupric oxide or basic cupric carbonate. … According to the good manufacturing or feeding practice by the FDA, copper gluconate is used as a nutrient or dietary supplement and is generally recognized as safe for use at a level not exceeding 0.005

    Mixtures: Zinc 50mg Tab
  6. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [L47850] In August 18, 2023, pozelimab was approved by the FDA for the treatment of CHAPLE disease. It is currently the only treatment explicitly indicated for CHAPLE disease.[L47875]

  7. Drug

    Cefamandole

    go.drugbank.com/drugs/DB01326
    ApprovedWithdrawn

    Cefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, cefamandole nafate. It is no longer marketed in the United States.

  8. Drug

    Kappadione

    go.drugbank.com/drugs/DB09332
    Approved

    Kappadione is a Vitamin K derivative (chemically, it is menadiol sodium diphosphate), previously approved by FDA prior to 1982 and marketed by Lilly Marketing for this drug has been discontinued and is

  9. Drug

    Magnesium oxide

    go.drugbank.com/drugs/DB01377
    ApprovedInvestigational

    Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses.

    Mixtures: Cyclo/Mag 10mg/200mgProducts: Magnesium Oxide Tab 70mg
  10. Drug

    Guanethidine

    go.drugbank.com/drugs/DB01170
    ApprovedWithdrawn

    An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. … It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.

    Products: Guanethidine 10 Tab 10mg, Apo Guanethidine Sulfate Tab 10mg